Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Fate Therapeutics Inc chart...

About the Company

fate therapeutics is applying leading expertise in stem cell biology and conventional drug discovery to develop small molecule and biologic drugs that: 1) activate stem cells in the body to stimulate healing and repair or block cancer growth; and 2) create and differentiate "pharmaceutical grade"​ ips cells to enable their use in drug discovery and development, disease modeling, and eventually personalized cell therapies. the company’s approach has broad therapeutic potential in areas such as regenerative medicine, hematological diseases, metastatic cancer, traumatic injury and degenerative diseases.

CEO

John Wolchko

Exchange

NASDAQ

Website

http://fatetherapeutics.com/

$236M

Total Revenue

482

Employees

$739M

Market Capitalization

-4.06

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $FATE News

Fate Therapeutics Inc FATE

3d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

FATE Apr 2024 7.500 put

2d ago, source: Yahoo Finance

Fate Therapeutics, Inc. (NASDAQ:FATE) Q4 2023 Earnings Call Transcript February 26, 2024 Fate Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.45, expectations were $-0.57. Fate ...

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

13d ago, source:

About Fate Therapeutics’ iPSC Product Platform The Company’s proprietary induced pluripotent stem cell (iPSC) product platform enables mass production of off-the-shelf, multiplexed-engineered cell ...

FATE Aug 2024 5.000 put

2d ago, source: Yahoo Finance

Fate Therapeutics, Inc. (NASDAQ:FATE) Q4 2023 Earnings Call Transcript February 26, 2024 Fate Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.45, expectations were $-0.57. Fate ...

Boundless Bio Starts $100 Million U.S. IPO Plan

6d ago, source:

Boundless Bio filed for $a 100M IPO to develop DNA treatments for cancer, and its lead candidate is in Phase 1 trials. Click here to learn more about BOLD.

Vindictus: Defying Fate is worth trying for free even if you never played the MMO

on MSN ago, source:

The more timid playstyle she encourages did help me get used to the basics of Vindictus: Defying Fate and overcome the first ...

Jurors Weigh Fate of Afghan Refugee Charged With Murder in a Case That Shocked Muslim Community

3d ago, source:

Prosecutors have wrapped up their case against an Afghan refugee in the first of three trials stemming from allegations that ...

You can check out Celtic-fantasy action RPG Vindictus: Defying Fate until next week in its free pre-alpha test

5d ago, source: Rock Paper Shotgun

The pre-alpha public test is live from now until next Monday, March 18th, with Nexon asking for players’ thoughts on their ...

Vindictus: Defying Fate public pre-alpha play test set for March 13 to 18

11d ago, source: gematsu

Nexon will host a public pre-alpha play test for newly announced action RPG Vindictus: Defying Fate from March 13 to 6:00 p.m ...

Nothing But Thieves Drop ‘Time :: Fate :: Karma :: God’ Track With ‘Dead Club City Deluxe’

3d ago, source: Rock Sound

Nothing But Thieves have shared their ‘Dead Club City Deluxe’ today, which features almighty new track ‘Time :: Fate :: Karma ...

Vindictus: Defying Fate Public Pre-Alpha Playtest Announced

11d ago, source: TechRaptor

If you're a Vindictus fan or simply like fast-paced action RPGs, you may want to try the public pre-alpha playtest on Steam ...

'Vindictus: Defying Fate' Pre-Alpha PC Playtest Begins Today

5d ago, source: Worth Playing

Vindictus: Defying Fate is a fast-paced action RPG, set in a visually stunning 3D fantasy world inspired by Celtic mythology.

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...